Santos, Raul D.

Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity

Ross, R., Neeland, I. J., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., Cuevas, A., Hu, F. B., et al. (2020) · Nature Reviews Endocrinology

Diabetes, Cardiovascular Risks, and LipoproteinsBody Composition Measurement Techniques

Cited by 1,966

Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement

Neeland, I. J., Ross, R., Després, J.-P., Matsuzawa, Y., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., et al. (2019) · The Lancet Diabetes & Endocrinology

Cardiovascular Disease and AdiposityDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,603

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment

Wiegman, A., Gidding, S. S., Watts, G. F., Chapman, M. J., Ginsberg, H. N., Cuchel, M., Ose, L., Averna, M., Boileau, C., Borén, J., et al. (2015) · European Heart Journal

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 891

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 749

The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association

Gidding, S. S., Ann Champagne, M., de Ferranti, S. D., Defesche, J., Ito, M. K., Knowles, J. W., McCrindle, B., Raal, F., Rader, D., Santos, R. D., et al. (2015) · Circulation

Lipoproteins and Cardiovascular HealthCardiovascular Health and Risk Factors

Cited by 723

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management

Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 635

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

Ridker, P. M., Revkin, J., Amarenco, P., Brunell, R., Curto, M., Civeira, F., Flather, M., Glynn, R. J., Gregoire, J., Jukema, J. W., et al. (2017) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 624

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

Mach, F., Ray, K. K., Wiklund, O., Corsini, A., Catapano, A. L., Bruckert, E., De Backer, G., Hegele, R. A., Hovingh, G. K., Jacobson, T. A., et al. (2018) · European Heart Journal

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 370

Lipid-reduction variability and antidrug-antibody formation with bococizumab

Ridker, P. M., Tardif, J.-C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W., Kastelein, J. J. P., Kim, A. M., Koenig, W., Nissen, S., et al. (2017) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 369

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 140

Marked HDL deficiency and premature coronary heart disease

Schaefer, E. J., Santos, R. D., & Asztalos, B. F. (2010) · Current Opinion in Lipidology

Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

Cited by 127

Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study

Blom, D. J., O'Dea, L., Digenio, A., Alexander, V. J., Karwatowska-Prokopczuk, E., Williams, K. R., Hemphill, L., Muñiz-Grijalvo, O., Santos, R. D., Baum, S., et al. (2018) · Journal of Clinical Lipidology

Lipid metabolism and disordersLymphatic Disorders and Treatments

Cited by 82

Lipid Lowering Drugs: Present Status and Future Developments

Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 73

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia

Grundy, S. M., Arai, H., Barter, P., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A., Davidson, M. H., Genest, J., Kesäniemi, Y. A., et al. (2014) · Atherosclerosis

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 68

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia

Ito, M. K., & Santos, R. D. (2017) · The Journal of Clinical Pharmacology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 59

World Heart Federation Cholesterol Roadmap

Murphy, A., Faria-Neto, J. R., Al-Rasadi, K., Blom, D., Catapano, A., Cuevas, A., Lopez-Jimenez, F., Perel, P., Santos, R., Sniderman, A., et al. (2017) · Global Heart

Lipoproteins and Cardiovascular HealthHealth Promotion and Cardiovascular Prevention

Cited by 43

A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2

Santos, R. D., Waters, D. D., Tarasenko, L., Messig, M., Jukema, J. W., Chiang, C.-W., Ferrieres, J., & Foody, J. M. (2012) · Atherosclerosis

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 39

Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome

Jamal, O., Aneni, E. C., Shaharyar, S., Ali, S. S., Parris, D., McEvoy, J. W., Veledar, E., Blaha, M. J., Blumenthal, R. S., Agatston, A. S., et al. (2014) · Diabetology & Metabolic Syndrome

Adipokines, Inflammation, and Metabolic DiseasesSmoking Behavior and Cessation

Cited by 30

The association between triglyceride-rich lipoproteins, circulating leukocytes, and low-grade inflammation: The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)

Cesena, F. Y., Generoso, G., Santos, R. D., Pereira, A. C., Blaha, M. J., Jones, S. R., Toth, P. P., Lotufo, P. A., Bittencourt, M. S., & Benseñor, I. M. (2023) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 15

First Report of Inclisiran Utilization for Hypercholesterolemia Treatment in Real-world Clinical Settings in a Middle East Population

Iqbal, S., Sabbour, H. M., Ashraf, T., Santos, R. D., & Buckley, A. (2024) · Clinical Therapeutics

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 13